Generic placeholder image

Current Nutraceuticals

Author(s): Luciene De Paula Mendes, Sharif Beyah and Erik Hefti*

DOI: 10.2174/2665978602666211124093814

DownloadDownload PDF Flyer Cite As
Anti-infective and Antineoplastic Properties of Green Tea Catechins: Examining the Therapeutic Risk-benefit Ratio

Article ID: e241121198250 Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Background: Green tea is a commonly used dietary supplement and food product. Green tea contains many polyphenolic compounds known as Green Tea Catechins (GTCs). There are numerous reports exploring the potential benefit of using green tea catechins as chemotherapeutic agents to treat neoplastic disorders and infectious processes. The prevalence of cancer diagnoses, bacterial infections, and viral diseases that include SARS-CoV-2 have led to increased interest in GTCs as a therapeutic option in patients suffering from these conditions.

Objective: This concise review explores the evidence related to the therapeutic use of GTCs to treat neoplastic disorders as well as bacterial and viral infections.

Methods: PubMed, NIH, and OVID online databases were utilized to retrieve relevant scientific literature that addresses GTCs role in treating cancer and infectious disease.

Results: While there are preliminary data indicating potentially adventitious properties of GTCs, there is a paucity of large prospective clinical trial data to support the use of GTCs in a therapeutic capacity to treat these disease processes. There are documented instances of GTCs interacting with medications indicated to treat neoplastic diseases.

Conclusion: Currently, it seems that the therapeutic benefit of using GTCs is outweighed by the potential risks.

Keywords: Green tea catechin, epigallocatechin, epicatechin-3-gallate, epigallocatechin-3-gallate, cancer, antimicrobial, nutraceutical, epicatechin.

Graphical Abstract

[1]
Graziose, R.; Lila, M.A.; Raskin, I. Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional foods. Curr. Drug Discov. Technol., 2010, 7(1), 2-12.
[http://dx.doi.org/10.2174/157016310791162767] [PMID: 20156139]
[2]
Bhagwat, S.; Beecher, G.; Haytowitz, D.; Holden, J.; Dwyer, J.; Peterson, J.; Gebhardt, S.; Eldridge, A.; Agarwal, S.; Balentine, D. 2003. Flavonoid composition of tea: Comparison of black and green teas. Agricultural Research Service. USDA database for the flavonoid content of selected foods. Available from: http://www.nal. usda.gov/fnic/foodcomp
[3]
Gopal, J.; Muthu, M.; Paul, D.; Kim, D-H.; Chun, S. Bactericidal activity of green tea extracts: The importance of catechin containing nano particles. Sci. Rep., 2016, 6, 19710-19710.
[http://dx.doi.org/10.1038/srep19710] [PMID: 26818408]
[4]
Reygaert, W.C. The antimicrobial possibilities of green tea. Front. Microbiol., 2014, 5, 434-434.
[http://dx.doi.org/10.3389/fmicb.2014.00434] [PMID: 25191312]
[5]
Chacko, S.M.; Thambi, P.T.; Kuttan, R.; Nishigaki, I. Beneficial effects of green tea: A literature review. Chin. Med., 2010, 5(1), 13.
[http://dx.doi.org/10.1186/1749-8546-5-13] [PMID: 20370896]
[6]
Graham, H.N. Green tea composition, consumption, and polyphenol chemistry. Prev. Med., 1992, 21(3), 334-350.
[http://dx.doi.org/10.1016/0091-7435(92)90041-F] [PMID: 1614995]
[7]
Farhan, M.; Shamim, U.; Hadi, S. Green Tea Polyphenols: A putative mechanism for cytotoxic action against cancer cells. Nutraceuticals and Natural Product Derivatives: Disease Prevention & Drug Discovery, 2019, 305-332.
[http://dx.doi.org/10.1002/9781119436713]
[8]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[9]
Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420(6917), 860-867.
[http://dx.doi.org/10.1038/nature01322] [PMID: 12490959]
[10]
Fung, M.; Babik, J.M. COVID-19 in immunocompromised hosts: What we know so far. Clin. Infect. Dis., 2021, 72(2), 340-350.
[http://dx.doi.org/10.1093/cid/ciaa863] [PMID: 33501974]
[11]
Steinmann, J.; Buer, J.; Pietschmann, T.; Steinmann, E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol., 2013, 168(5), 1059-1073.
[http://dx.doi.org/10.1111/bph.12009] [PMID: 23072320]
[12]
Xu, J.; Xu, Z.; Zheng, W. A review of the antiviral role of green tea catechins. Molecules, 2017, 22(8), 1337.
[http://dx.doi.org/10.3390/molecules22081337] [PMID: 28805687]
[13]
Zhou, Y.; Yao, Q.; Zhang, T.; Chen, X.; Wu, Z.; Zhang, N.; Shao, Y.; Cheng, Y. Antibacterial activity and mechanism of green tea polysaccharide conjugates against Escherichia coli. Ind. Crops Prod., 2020, 152, 112464.
[http://dx.doi.org/10.1016/j.indcrop.2020.112464]
[14]
Bhandari, K.; De, B.; Goswami, T.K. Evidence based seasonal variances in catechin and caffeine content of tea. SN Appl Sci, 2019, 1(12), 1-6.
[http://dx.doi.org/10.1007/s42452-019-1766-8]
[15]
Lee, M-J.; Maliakal, P.; Chen, L.; Meng, X.; Bondoc, F.Y.; Prabhu, S.; Lambert, G.; Mohr, S.; Yang, C.S. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3- gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol. Biomarkers Prev., 2002, 11(10 Pt 1), 1025-1032.
[PMID: 12376503]
[16]
Oketch-Rabah, H.A.; Roe, A.L.; Rider, C.V.; Bonkovsky, H.L.; Giancaspro, G.I.; Navarro, V.; Paine, M.F.; Betz, J.M.; Marles, R.J.; Casper, S.; Gurley, B.; Jordan, S.A.; He, K.; Kapoor, M.P.; Rao, T.P.; Sherker, A.H.; Fontana, R.J.; Rossi, S.; Vuppalanchi, R.; Seeff, L.B.; Stolz, A.; Ahmad, J.; Koh, C.; Serrano, J.; Low Dog, T.; Ko, R. United States pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. Toxicol. Rep., 2020, 7, 386-402.
[http://dx.doi.org/10.1016/j.toxrep.2020.02.008] [PMID: 32140423]
[17]
Rubab, S.; Rizwani, G.H.; Bahadur, S.; Shah, M.; Alsamadany, H.; Alzahrani, Y.; Shuaib, M.; Hershan, A.; Hobani, Y.H.; Shah, A.A. Determination of the GC–MS analysis of seed oil and assessment of pharmacokinetics of leaf extract of camellia sinensis L. J. King Saud Univ. Sci., 2020, 32(7), 3138-3144.
[http://dx.doi.org/10.1016/j.jksus.2020.08.026]
[18]
Chu, K. O.; Pang, C. C. Pharmacokinetics And Disposition Of Green Tea Catechins. Pharmacokinetics and Adverse Effects of Drugs: Mechanisms and Risks Factors, 2018, Vol. 17
[http://dx.doi.org/10.5772/intechopen.74190]
[19]
Clifford, M.N.; van der Hooft, J.J.; Crozier, A. Human studies on the absorption, distribution, metabolism, and excretion of tea polyphenols. Am. J. Clin. Nutr., 2013, 98(6)(Suppl.), 1619S-1630S.
[http://dx.doi.org/10.3945/ajcn.113.058958] [PMID: 24172307]
[20]
Roth, M.; Timmermann, B.N.; Hagenbuch, B. Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab. Dispos., 2011, 39(5), 920-926.
[http://dx.doi.org/10.1124/dmd.110.036640] [PMID: 21278283]
[21]
Kim, T-E.; Ha, N.; Kim, Y.; Kim, H.; Lee, J.W.; Jeon, J-Y.; Kim, M-G. Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers. Drug Des. Devel. Ther., 2017, 11, 1409-1416.
[http://dx.doi.org/10.2147/DDDT.S130050] [PMID: 28533679]
[22]
Misaka, S.; Yatabe, J.; Müller, F.; Takano, K.; Kawabe, K.; Glaeser, H.; Yatabe, M.S.; Onoue, S.; Werba, J.P.; Watanabe, H.; Yamada, S.; Fromm, M.F.; Kimura, J. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin. Pharmacol. Ther., 2014, 95(4), 432-438.
[http://dx.doi.org/10.1038/clpt.2013.241] [PMID: 24419562]
[23]
Albassam, A.A.; Markowitz, J.S. An appraisal of drug-drug interactions with green tea (camellia sinensis). Planta Med., 2017, 83(6), 496-508.
[http://dx.doi.org/10.1055/s-0043-100934] [PMID: 28118673]
[24]
Huang, X.; Zhang, R.; Yang, T.; Wei, Y.; Yang, C.; Zhou, J.; Liu, Y.; Shi, S. Inhibition effect of epigallocatechin-3-gallate on the pharmacokinetics of calcineurin inhibitors, tacrolimus, and cyclosporine A, in rats. Expert Opin. Drug Metab. Toxicol., 2021, 17(1), 121-134.
[http://dx.doi.org/10.1080/17425255.2021.1837111] [PMID: 33054444]
[25]
Scholl, C.; Lepper, A.; Lehr, T.; Hanke, N.; Schneider, K.L.; Brockmöller, J.; Seufferlein, T.; Stingl, J.C. Population nutrikinetics of green tea extract. PLoS One, 2018, 13(2), e0193074.
[http://dx.doi.org/10.1371/journal.pone.0193074] [PMID: 29466429]
[26]
Kim, T-E.; Shin, K-H.; Park, J-E.; Kim, M-G.; Yun, Y-M.; Choi, D-H.; Kwon, K.J.; Lee, J. Effect of green tea catechins on the pharmacokinetics of digoxin in humans. Drug Des. Devel. Ther., 2018, 12, 2139-2147.
[http://dx.doi.org/10.2147/DDDT.S148257] [PMID: 30022812]
[27]
Chow, H.H.; Hakim, I.A.; Vining, D.R.; Crowell, J.A.; Cordova, C.A.; Chew, W.M.; Xu, M.J.; Hsu, C.H.; Ranger-Moore, J.; Alberts, D.S. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol. Biomarkers Prev., 2006, 15(12), 2473-2476.
[http://dx.doi.org/10.1158/1055-9965.EPI-06-0365] [PMID: 17164372]
[28]
Netsch, M.I.; Gutmann, H.; Schmidlin, C.B.; Aydogan, C.; Drewe, J. Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med., 2006, 72(6), 514-520.
[http://dx.doi.org/10.1055/s-2006-931537] [PMID: 16773535]
[29]
Chen, L.; Bondoc, F.Y.; Lee, M.J.; Hussin, A.H.; Thomas, P.E.; Yang, C.S. Caffeine induces cytochrome P4501A2: Induction of CYP1A2 by tea in rats. Drug Metab. Dispos., 1996, 24(5), 529-533.
[PMID: 8723732]
[30]
Zaragoza, M.V.; Brandon, M.C.; Diegoli, M.; Arbustini, E.; Wallace, D.C. Mitochondrial cardiomyopathies: How to identify candidate pathogenic mutations by mitochondrial DNA sequencing, MITOMASTER and phylogeny. Eur. J. Hum. Genet., 2011, 19(2), 200-207.
[http://dx.doi.org/10.1038/ejhg.2010.169] [PMID: 20978534]
[31]
Misaka, S.; Ono, Y.; Uchida, A.; Ono, T.; Abe, O.; Ogata, H.; Sato, H.; Suzuki, M.; Onoue, S.; Shikama, Y.; Shimomura, K. Impact of green tea catechin ingestion on the pharmacokinetics of lisinopril in healthy volunteers. Clin. Transl. Sci., 2021, 14(2), 476-480.
[http://dx.doi.org/10.1111/cts.12905] [PMID: 33048477]
[32]
Filippini, T.; Malavolti, M.; Borrelli, F.; Izzo, A. A.; Fairweather‐Tait, S. J.; Horneber, M.; Vinceti, M. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Sys Rev, 2020, 3(3), CD005004.
[http://dx.doi.org/10.1002/14651858.CD005004.pub3] [PMID: 32118296]
[33]
Shirakami, Y.; Shimizu, M. Possible mechanisms of green tea and its constituents against cancer. Molecules, 2018, 23(9), 2284.
[http://dx.doi.org/10.3390/molecules23092284] [PMID: 30205425]
[34]
Niedzwiecki, A.; Roomi, M.W.; Kalinovsky, T.; Rath, M. Anticancer efficacy of polyphenols and their combinations. Nutrients, 2016, 8(9), 552.
[http://dx.doi.org/10.3390/nu8090552] [PMID: 27618095]
[35]
Gupta, S.; Hastak, K.; Afaq, F.; Ahmad, N.; Mukhtar, H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene, 2004, 23(14), 2507-2522.
[http://dx.doi.org/10.1038/sj.onc.1207353] [PMID: 14676829]
[36]
Park, M.H.; Hong, J.T. Roles of NF-κB in Cancer and inflammatory diseases and their therapeutic approaches. Cells, 2016, 5(2), 15.
[http://dx.doi.org/10.3390/cells5020015] [PMID: 27043634]
[37]
Shankar, S.; Marsh, L.; Srivastava, R.K. EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Mol. Cell. Biochem., 2013, 372(1-2), 83-94.
[http://dx.doi.org/10.1007/s11010-012-1448-y] [PMID: 22971992]
[38]
Zhao, X.; Fan, W.; Xu, Z.; Chen, H.; He, Y.; Yang, G.; Yang, G.; Hu, H.; Tang, S.; Wang, P.; Zhang, Z.; Xu, P.; Yu, M. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma. Oncotarget, 2016, 7(49), 81110-81122.
[http://dx.doi.org/10.18632/oncotarget.13212] [PMID: 27835602]
[39]
Kürbitz, C.; Heise, D.; Redmer, T.; Goumas, F.; Arlt, A.; Lemke, J.; Rimbach, G.; Kalthoff, H.; Trauzold, A. Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Cancer Sci., 2011, 102(4), 728-734.
[http://dx.doi.org/10.1111/j.1349-7006.2011.01870.x] [PMID: 21241417]
[40]
Tsao, A.S.; Liu, D.; Martin, J.; Tang, X.M.; Lee, J.J.; El-Naggar, A.K.; Wistuba, I.; Culotta, K.S.; Mao, L.; Gillenwater, A.; Sagesaka, Y.M.; Hong, W.K.; Papadimitrakopoulou, V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev. Res. (Phila.), 2009, 2(11), 931-941.
[http://dx.doi.org/10.1158/1940-6207.CAPR-09-0121] [PMID: 19892663]
[41]
Jatoi, A.; Ellison, N.; Burch, P.A.; Sloan, J.A.; Dakhil, S.R.; Novotny, P.; Tan, W.; Fitch, T.R.; Rowland, K.M.; Young, C.Y.; Flynn, P.J. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer, 2003, 97(6), 1442-1446.
[http://dx.doi.org/10.1002/cncr.11200] [PMID: 12627508]
[42]
Lane, J.A.; Er, V.; Avery, K.N.L.; Horwood, J.; Cantwell, M.; Caro, G.P.; Crozier, A.; Smith, G.D.; Donovan, J.L.; Down, L.; Hamdy, F.C.; Gillatt, D.; Holly, J.; Macefield, R.; Moody, H.; Neal, D.E.; Walsh, E.; Martin, R.M.; Metcalfe, C. ProDiet: A phase II randomized placebo-controlled trial of green tea catechins and lycopene in men at increased risk of prostate cancer. Cancer Prev. Res. (Phila.), 2018, 11(11), 687-696.
[http://dx.doi.org/10.1158/1940-6207.CAPR-18-0147] [PMID: 30309839]
[43]
Guo, Y.; Zhi, F.; Chen, P.; Zhao, K.; Xiang, H.; Mao, Q.; Wang, X.; Zhang, X. Green tea and the risk of prostate cancer: A systematic review and meta-analysis. Medicine (Baltimore), 2017, 96(13), e6426-e6426.
[http://dx.doi.org/10.1097/MD.0000000000006426] [PMID: 28353571]
[44]
Samavat, H.; Ursin, G.; Emory, T.H.; Lee, E.; Wang, R.; Torkelson, C.J.; Dostal, A.M.; Swenson, K.; Le, C.T.; Yang, C.S.; Yu, M.C.; Yee, D.; Wu, A.H.; Yuan, J.M.; Kurzer, M.S. A randomized controlled trial of green tea extract supplementation and mammographic density in postmenopausal women at increased risk of breast cancer. Cancer Prev. Res. (Phila.), 2017, 10(12), 710-718.
[http://dx.doi.org/10.1158/1940-6207.CAPR-17-0187] [PMID: 28904061]
[45]
Yu, Z.; Samavat, H.; Dostal, A.M.; Wang, R.; Torkelson, C.J.; Yang, C.S.; Butler, L.M.; Kensler, T.W.; Wu, A.H.; Kurzer, M.S.; Yuan, J.M. Effect of green tea supplements on liver enzyme elevation: Results from a randomized intervention study in the United States. Cancer Prev. Res. (Phila.), 2017, 10(10), 571-579.
[http://dx.doi.org/10.1158/1940-6207.CAPR-17-0160] [PMID: 28765194]
[46]
Najaf Najafi, M.; Salehi, M.; Ghazanfarpour, M.; Hoseini, Z.S.; Khadem-Rezaiyan, M. The association between green tea consumption and breast cancer risk: A systematic review and meta-analysis. Phytother. Res., 2018, 32(10), 1855-1864.
[http://dx.doi.org/10.1002/ptr.6124] [PMID: 29876987]
[47]
McNaught, J. On the action of cold or lukewarm tea on Bacillus typhosus. BMJ Military Health, 1906, 7(4), 372-373.
[http://dx.doi.org/10.1136/JRAMC-07-04-08]
[48]
Hamilton-Miller, J. Microbiological properties of tea infusions. Chemical and biological properties of tea infusions; Deutscher Medizinischer Imformationsdienst: Frankfurt am Main, Germany, 1997, pp. 63-75.
[49]
Taylor, P.W.; Hamilton-Miller, J.M.T.; Stapleton, P.D. Antimicrobial properties of green tea catechins. Food Sci. Technol. Bull., 2005, 2, 71-81.
[http://dx.doi.org/10.1616/1476-2137.14184] [PMID: 19844590]
[50]
Stapleton, P.D.; Shah, S.; Anderson, J.C.; Hara, Y.; Hamilton-Miller, J.M.T.; Taylor, P.W. Modulation of β-lactam resistance in Staphylococcus aureus by catechins and gallates. Int. J. Antimicrob. Agents, 2004, 23(5), 462-467.
[http://dx.doi.org/10.1016/j.ijantimicag.2003.09.027] [PMID: 15120724]
[51]
Kheirabadi, Z.; Mehrabani, M.; Sarafzadeh, F.; Dabaghzadeh, F.; Ahmadinia, N. Green tea as an adjunctive therapy for treatment of acute uncomplicated cystitis in women: A randomized clinical trial. Complement. Ther. Clin. Pract., 2019, 34, 13-16.
[http://dx.doi.org/10.1016/j.ctcp.2018.10.018] [PMID: 30712716]
[52]
Reygaert, W.C. Green tea catechins: Their use in treating and preventing infectious diseases. BioMed Res. Int., 2018, 2018, 9105261.
[http://dx.doi.org/10.1155/2018/9105261] [PMID: 30105263]
[53]
Dib, K.; Ennibi, O.; Alaoui, K.; Cherrah, Y.; Filali-Maltouf, A. Antibacterial activity of plant extracts against periodontal pathogens: A systematic review. J. Herb. Med., 2021, 29, 100493.
[http://dx.doi.org/10.1016/j.hermed.2021.100493]
[54]
Falcinelli, S.D.; Shi, M.C.; Friedlander, A.M.; Chua, J. Green tea and epigallocatechin-3-gallate are bactericidal against Bacillus anthracis. FEMS Microbiol. Lett., 2017, 364(12)
[http://dx.doi.org/10.1093/femsle/fnx127] [PMID: 28605495]
[55]
Mehrad, B.; Clark, N.M.; Zhanel, G.G.; Lynch, J.P., III Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest, 2015, 147(5), 1413-1421.
[http://dx.doi.org/10.1378/chest.14-2171] [PMID: 25940252]
[56]
Chaturvedi, V.; Kaore, S.; Kaore, N.; Kaur, S.; Gautam, S. Evaluation of the antimicrobial property of green tea extract and its synergistic effect on antimicrobials showing resistance in clinical isolates of a tertiary care hospital. J. Mahatma Gandhi Institute of Med. Sci., 2019, 24(1), 33-38.
[http://dx.doi.org/10.4103/jmgims.jmgims_56_18]
[57]
Hamulka, J.; Jeruszka-Bielak, M.; Górnicka, M.; Drywień, M.E.; Zielinska-Pukos, M.A. Dietary supplements during COVID-19 outbreak. Results of Google trends analysis supported by PLifeCOVID-19 online studies. Nutrients, 2020, 13(1), 54.
[http://dx.doi.org/10.3390/nu13010054] [PMID: 33375422]
[58]
Ghosh, R.; Chakraborty, A.; Biswas, A.; Chowdhuri, S. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study. J. Biomol. Struct. Dyn., 2021, 39(12), 4362-4374.
[http://dx.doi.org/10.1080/07391102.2020.1779818] [PMID: 32568613]
[59]
Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R. Crystal structure of SARS- CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, 2020, 368(6489), 409-412.
[http://dx.doi.org/10.1126/science.abb3405] [PMID: 32198291]
[60]
Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; Duan, Y.; Yu, J.; Wang, L.; Yang, K.; Liu, F.; Jiang, R.; Yang, X.; You, T.; Liu, X.; Yang, X.; Yang, H. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature, 2020, 582(7811), 289-293.
[http://dx.doi.org/10.1038/s41586-020-2223-y] [PMID: 32272481]
[61]
Zhang, Z.; Zhang, X.; Bi, K.; He, Y.; Yan, W.; Yang, C.S.; Zhang, J. Potential protective mechanisms of green tea polyphenol EGCG against COVID-19. Trends Food Sci. Technol., 2021, 114, 11-24.
[http://dx.doi.org/10.1016/j.tifs.2021.05.023] [PMID: 34054222]
[62]
Mhatre, S.; Srivastava, T.; Naik, S.; Patravale, V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review. Phytomedicine, 2021, 85, 153286.
[http://dx.doi.org/10.1016/j.phymed.2020.153286] [PMID: 32741697]
[63]
Storozhuk, M. COVID-19: Could green tea catechins reduce the risks? MedRxiv, 2021. Preprint Paper.
[http://dx.doi.org/10.1101/2020.10.23.20218479]
[64]
Song, J.M.; Lee, K.H.; Seong, B.L. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res., 2005, 68(2), 66-74.
[http://dx.doi.org/10.1016/j.antiviral.2005.06.010] [PMID: 16137775]
[65]
Matsumoto, K.; Yamada, H.; Takuma, N.; Niino, H.; Sagesaka, Y.M. Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: A randomized controlled trial. BMC Complement. Altern. Med., 2011, 11, 15-15.
[http://dx.doi.org/10.1186/1472-6882-11-15] [PMID: 21338496]
[66]
Rawangkan, A.; Kengkla, K.; Kanchanasurakit, S.; Duangjai, A.; Saokaew, S. Anti-influenza with green tea catechins: A systematic review and meta-analysis. Molecules, 2021, 26(13), 4014.
[http://dx.doi.org/10.3390/molecules26134014] [PMID: 34209247]
[67]
Kumar, N.B.; Pow-Sang, J.; Spiess, P.E.; Park, J.; Salup, R.; Williams, C.R.; Parnes, H.; Schell, M.J. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget, 2016, 7(43), 70794-70802.
[http://dx.doi.org/10.18632/oncotarget.12222] [PMID: 28053292]
[68]
Chow, H.H.; Cai, Y.; Hakim, I.A.; Crowell, J.A.; Shahi, F.; Brooks, C.A.; Dorr, R.T.; Hara, Y.; Alberts, D.S. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res., 2003, 9(9), 3312-3319.
[PMID: 12960117]
[69]
Hodgson, J.M.; Puddey, I.B.; Burke, V.; Beilin, L.J.; Jordan, N. Effects on blood pressure of drinking green and black tea. J. Hypertens., 1999, 17(4), 457-463.
[http://dx.doi.org/10.1097/00004872-199917040-00002] [PMID: 10404946]
[70]
Peng, X.; Zhou, R.; Wang, B.; Yu, X.; Yang, X.; Liu, K.; Mi, M. Effect of green tea consumption on blood pressure: A meta-analysis of 13 randomized controlled trials. Sci. Rep., 2014, 4, 6251.
[http://dx.doi.org/10.1038/srep06251] [PMID: 25176280]
[71]
Golden, E.B.; Lam, P.Y.; Kardosh, A.; Gaffney, K.J.; Cadenas, E.; Louie, S.G.; Petasis, N.A.; Chen, T.C.; Schönthal, A.H. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood, 2009, 113(23), 5927-5937.
[http://dx.doi.org/10.1182/blood-2008-07-171389] [PMID: 19190249]
[72]
Seeram, N.P.; Henning, S.M.; Niu, Y.; Lee, R.; Scheuller, H.S.; Heber, D. Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. J. Agric. Food Chem., 2006, 54(5), 1599-1603.
[http://dx.doi.org/10.1021/jf052857r] [PMID: 16506807]
[73]
Lee, L-S.; Kim, S-H.; Kim, Y-B.; Kim, Y-C. Quantitative analysis of major constituents in green tea with different plucking periods and their antioxidant activity. Molecules, 2014, 19(7), 9173-9186.
[http://dx.doi.org/10.3390/molecules19079173] [PMID: 24988187]